Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Sep 11, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Terns Pharmaceuticals, Inc.
|
0
|
$5.91 | -$140,982.30 |
—
| 15K |
Sep 9
| |||||||
Terns Pharmaceuticals, Inc.
|
0
|
$5.91 | -$120,787.76 |
—
| 30K |
Jul 15 - Jul 16
| |||||||
Terns Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 10
| |||||||
Terns Pharmaceuticals, Inc.
| 15K |
—
|
—
| +100.00% | 30K |
Jan 23
| |||||||
Terns Pharmaceuticals, Inc.
| 15K |
—
|
—
|
∞
| 15K |
Nov 15
| |||||||
Chemomab Therapeutics Ltd.
|
0
|
—
|
—
|
—
|
0
|
Jun 16 - Jun 16
| |||||||
Terns Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 12
| |||||||
Terns Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 16
| |||||||
Chemomab Therapeutics Ltd.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Passage Bio, Inc.
| 71.97K |
$0.23 | $16,554.25 | +24.25% | 368.75K |
Dec 8
| |||||||
Terns Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
|
Sep 28
| |||||||
Passage Bio, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 16
| |||||||
Terns Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Passage Bio, Inc.
| -1.30K |
$30.01 | -$39,011.05 | -0.44% | 295.28K |
Jan 20
|
Scheduled
| ||||||
Passage Bio, Inc.
| 16.3K |
$30.10 | $490,569.80 | +5.81% | 296.58K |
Jan 14
|
Scheduled
| ||||||
Passage Bio, Inc.
| 2.5K |
$18.00 | $45,000.00 | +0.81% | 312.49K |
Mar 3
| |||||||
Passage Bio, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 27
| |||||||
Passage Bio, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||